(0.29%) 5 114.68 points
(0.30%) 38 356 points
(0.31%) 15 978 points
(-0.95%) $83.05
(5.77%) $2.03
(0.37%) $2 355.90
(0.42%) $27.65
(3.99%) $958.85
(-0.22%) $0.933
(-0.38%) $10.98
(-0.53%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees...
Stats | |
---|---|
本日の出来高 | 826 006 |
平均出来高 | 401 776 |
時価総額 | 53.67M |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0.177 (8.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-06-30 | Dalal Anupam | Buy | 7 400 | Common Stock |
2021-06-30 | Castelein Caley | Buy | 7 811 | Common Stock |
2021-06-30 | Cohen Cheryl | Buy | 8 140 | Common Stock |
2021-06-17 | Cohen Cheryl | Buy | 100 000 | Stock Option (Right to Buy) |
2021-03-31 | Cohen Cheryl | Buy | 8 020 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 63 transactions |
Buy: 4 252 497 | Sell: 3 402 072 |
ボリューム 相関
Aerpio Pharmaceuticals 相関
10 最も負の相関 | |
---|---|
HWCC | -0.835 |
BIDU | -0.818 |
POWL | -0.811 |
OBAS | -0.808 |
RXDX | -0.806 |
LWAC | -0.806 |
FWONK | -0.806 |
BNIX | -0.806 |
BKNG | -0.804 |
FWONA | -0.803 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Aerpio Pharmaceuticals 相関 - 通貨/商品
Aerpio Pharmaceuticals 財務諸表
Annual | 2022 |
収益: | $5.51M |
総利益: | $-29.51M (-535.75 %) |
EPS: | $-1.080 |
FY | 2022 |
収益: | $5.51M |
総利益: | $-29.51M (-535.75 %) |
EPS: | $-1.080 |
Financial Reports:
No articles found.
Aerpio Pharmaceuticals
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。